Products for Research Use Only

(E/Z) -SU9516

CAT: 0804-HY-18629ASize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18629ASize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(E/Z) -SU9516 is the isomer of SU9516. SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC50s of 40, 200 nM, respectively.
CAS Number
666837-93-0
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Apoptosis; Autophagy; CDK
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/e-z-su9516.html
Smiles
O=C1NC2=C(C=C(OC)C=C2)/C1=C\C3=CN=CN3
Molecular Formula
C13H11N3O2
Molecular Weight
241.25
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Lane ME, et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001 Aug 15;61 (16) :6170-7.|[2]Yu B, et al. SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem Pharmacol. 2002 Oct 1;64 (7) :1091-100.|[3]Gao N, et al. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1- (3H-imidazol-4-yl) -meth- (Z) -ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol Pharmacol. 2006 Aug;70 (2) :645-55.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported